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Introduction
The questions when and how multiple sclerosis (MS) 
starts have been captivating researchers for decades, 
and in search for the trigger of MS two environmental 
risk factors have consistently been identified: infec-
tion with the Epstein–Barr virus (EBV) and a poor 
vitamin D status.
EBV is a human γ-herpesvirus, which infects and 
latently persists in B lymphocytes. The majority of 
the general population (±90%) shows serologic signs 
of EBV infection, but virtually all MS patients are 
EBV-seropositive.1 EBV infection occurs often 
asymptomatically during childhood, but primary 
infection after childhood can cause infectious mono-
nucleosis.2 The occurrence of infectious mononucleo-
sis is associated with an increased risk of developing 
MS.3 Moreover, higher antibody titers against EBV 
antigens have been found in MS, with the most domi-
nant response against the Epstein–Barr nuclear anti-
gen-1 (EBNA-1) (reviewed by Pender and Burrows4). 
Higher anti-EBNA-1 immunoglobulin (Ig) G levels 
are associated with an increased risk of MS,5 and in 
some but not all studies with a higher probability of 
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Abstract
Background: Epstein–Barr virus (EBV) infection and vitamin D insufficiency are potentially interacting 
risk factors for multiple sclerosis (MS).
Objectives: To investigate the effect of high-dose vitamin D3 supplements on antibody levels against the 
EBV nuclear antigen-1 (EBNA-1) in patients with relapsing-remitting multiple sclerosis (RRMS) and to 
explore any underlying mechanism affecting anti-EBNA-1 antibody levels.
Methods: This study utilized blood samples from a randomized controlled trial in RRMS patients receiv-
ing either vitamin D3 (14,000 IU/day; n = 30) or placebo (n = 23) over 48 weeks. Circulating levels of 
25-hydroxyvitamin-D, and anti-EBNA-1, anti-EBV viral capsid antigen (VCA), and anti-cytomegalovi-
rus (CMV) antibodies were measured. EBV load in leukocytes, EBV-specific cytotoxic T-cell responses, 
and anti-EBNA-1 antibody production in vitro were also explored.
Results: The median antibody levels against EBNA-1, but not VCA and CMV, significantly reduced in 
the vitamin D3 group (526 (368–1683) to 455 (380–1148) U/mL) compared to the placebo group (432 
(351–1280) to 429 (297–1290) U/mL; p = 0.023). EBV load and cytotoxic T-cell responses were unaf-
fected. Anti-EBNA-1 antibody levels remained below detection limits in B-cell cultures.
Conclusion: High-dose vitamin D3 supplementation selectively reduces anti-EBNA-1 antibody levels in 
RRMS patients. Our exploratory studies do not implicate a promoted immune response against EBV as 
the underlying mechanism.
Keywords: Antibodies, EBNA-1, Epstein–Barr virus, multiple sclerosis, supplementation, vitamin D
Date received: 21 April 2017; revised: 16 June 2017; accepted: 2 July 2017
Correspondence to: 
L Rolf  
School for Mental Health and 
Neuroscience, Maastricht 
University Medical Center, 
Universiteitssingel 40, 
6229 ER Maastricht, The 
Netherlands. 
linda.rolf@
maastrichtuniversity.nl
Linda Rolf  
School for Mental Health and 
Neuroscience, Maastricht 
University Medical Centre, 
Maastricht, The Netherlands/
Academic MS Center 
Limburg, Zuyderland 
Medical Center, Sittard, 
The Netherlands/Central 
Diagnostic Laboratory, 
Maastricht University 
Medical Centre, Maastricht, 
The Netherlands
Anne-Hilde Muris  
Raymond Hupperts  
School for Mental Health and 
Neuroscience, Maastricht 
University Medical Centre, 
Maastricht, The Netherlands/
Academic MS Center 
Limburg, Zuyderland 
Medical Center, Sittard, The 
Netherlands
Amandine Mathias  
Renaud Du Pasquier  
Laboratory of 
Neuroimmunology, Center of 
Research in Neurosciences, 
Department of Clinical 
Neurosciences, Lausanne 
University Hospital, 
Lausanne, Switzerland
Inga Koneczny  
School for Mental Health and 
Neuroscience, Maastricht 
University Medical Center, 
Maastricht, The Netherlands
Giulio Disanto  
Neurocenter of Southern 
Switzerland (NSI), Ospedale 
Civico, Lugano, Switzerland
Jens Kuhle  
Neurologic Clinic and 
Policlinic, Departments of 
Medicine, Biomedicine, and 
722646MSJ0010.1177/1352458517722646Multiple Sclerosis JournalL Rolf, A-H Muris
research-article2017
Original Research Paper
L Rolf, A-H Muris et al.
journals.sagepub.com/home/msj 1281
conversion from clinically isolated syndrome (CIS) to 
clinically definite MS.6,7 Several but not all studies 
found associations between anti-EBNA-1 antibodies 
and neurological disability6–8 as well as disease activ-
ity and cortical atrophy on magnetic resonance imag-
ing (MRI).7–10
A poor vitamin D status, reflected by low 25(OH)
D-levels, has been associated with an increased risk 
of developing MS,11 incidence of relapses,12 neuro-
logical disability,13,14 and MRI activity.15 This is 
thought to be the result of a lack of immune regulation 
by vitamin D. Experimental studies have demon-
strated regulatory properties of vitamin D on several 
immune cells, including inhibition of IgG production 
by plasma cells.16 Some small studies have shown 
that vitamin D3 supplementation may have beneficial 
effects on immune parameters in MS.17,18 Moreover, 
the SOLAR trial, a randomized controlled trial (RCT) 
on high-dose vitamin D3 supplementation as add-on 
therapy to interferon-beta, showed reduced MRI 
activity upon vitamin D3 supplementation in relaps-
ing-remitting multiple sclerosis (RRMS) patients as 
compared to placebo.19
Studies have shown that EBV infection and a poor 
vitamin D status are independently associated with MS 
risk.20 However, data suggesting an interaction between 
these two factors are also available. Increased anti-
EBNA-1 IgG and reduced 25(OH)D-levels have been 
observed prior to MS onset.21 Also, Wergeland et al.22 
recently showed a seasonal fluctuation in anti-EBNA-1 
IgG levels in RRMS patients, inversely to the fluctua-
tion of 25(OH)D-levels. Furthermore, we previously 
found that 12 weeks of high-dose vitamin D3 supple-
mentation reduced anti-EBNA-1 IgG levels in RRMS.23 
In a recent RCT, vitamin D3 supplements likewise 
selectively reduced anti-EBNA-1 IgG.24 We attempted 
to replicate these findings and to study the potential 
underlying mechanism by performing several explora-
tory studies using samples collected from a recent RCT 
with vitamin D3 supplements in RRMS. In addition 
to the influence of vitamin D on the EBV-specific 
antibody response, we assessed whether the viral load 
in leukocytes was affected, potentially by increased 
cytotoxic responses, and examined in vitro effects of 
vitamin D on antigen-specific antibody production.
Methods
Study and subject details
The effect of vitamin D3 supplementation on anti-
EBNA-1 IgG levels was studied as a secondary out-
come measure of the Dutch SOLARIUM, a sub-study 
of the SOLAR trial (NCT01285401). Detailed study 
procedures are described elsewhere.18,19 Participants 
were patients with RRMS according to the McDonald 
criteria,25 aged 18–55 years and treated with 
interferon-β1α (Rebif®, Merck, Geneva, Switzerland), 
who had a first clinical event in the previous 5 years 
and active disease, but no relapse 30 days before 
inclusion. Patients were randomized and allocated to 
a placebo or vitamin D3 group. Patients in the vitamin 
D3 group received cholecalciferol drops (Vigantol 
Oil, Merck) 7000 IU/day in the first 4 weeks, followed 
by 14,000 IU/day up to week 48. To study the in vitro 
effect of vitamin D on total and anti-EBNA-1 IgG 
production, blood samples were obtained from EBV-
seropositive healthy volunteers (HVs). Written 
informed consent was acquired and the study was 
approved by the Ethical Committee METC-Z 
(Heerlen, the Netherlands).
Vitamin D and antibody measurements
From SOLARIUM participants, blood was drawn 
before and after a 48-week study period for measure-
ments of several analytes, including serum 25(OH)
D-levels.18 Levels of IgG against the EBV antigens 
EBNA-1 and viral capsid antigen (VCA) and against 
the cytomegalovirus (CMV) were measured in plasma 
samples, which were stored at −20°C until analyses. 
Tests were performed using the quantitative LIAISON® 
EBNA, VCA, or CMV IgG assays (DiaSorin, Saluggia, 
Italy), which use chemiluminescence immunoassay 
technology. Results ⩾22 U/mL were considered posi-
tive. EBV seropositivity of HVs was assessed with the 
VIDAS® test for qualitative detection of anti-EBNA-1 
IgG (Biomerieux, Marcy-l’Étoile, France). Samples 
were considered positive in case of sample/standard 
indexes ⩾0.21.
Cell isolation
Peripheral blood mononuclear cells (PBMC) were 
isolated from venous blood as described previously.18 
PBMC of SOLARIUM participants were partly stored 
at −80°C in TRIzol® (Invitrogen, Paisley, Scotland, 
UK) until use for viral load assessments and partly 
stored in liquid nitrogen until use for detection of 
EBV-specific CD8+ T cells. PBMC of HVs were used 
for further B cell purifications, using an EasySep™ 
human B cell enrichment kit (Stemcell technologies, 
Vancouver, Canada) for negative selection of B lym-
phocytes. B cells were >98% pure in all but one 
(86.6%) of the suspensions.
Quantification of EBV viral loads with qPCR
DNA was extracted from 200 µL of the TRIzol sam-
ples, containing up to 2.5 × 106 PBMC in 1 mL, using 
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the MagnaPure 96 DNA and Viral NA small-volume 
kit (Roche Diagnostics, Mannheim, Germany) and the 
Pathogen Universal 200 protocol. The polymerase 
chain reaction (PCR) protocol and use of controls was 
described previously;26 for this study, an ABI 7900 
real-time quantitative PCR (RT-qPCR) apparatus 
(Applied Biosystems, Foster City, CA, USA) was 
used. The detection range of this EBV DNA PCR was 
200 – 1 × 106 copies/mL. Since the number of PBMC 
varied per sample, results are calculated and presented 
as EBV copies per 1 × 106 PBMC or 1 × 105 B cells as 
described in the legend of Table 2. In addition, relative 
expression to the reference gene HPRT was analyzed. 
Hereto, RNA was extracted from the remainder of the 
TRIzol samples. Quantity and quality control was per-
formed using a spectrophotometer (ND-2000, 
Nanodrop technologies, Rockland, DE, USA). Reverse 
transcription of total RNA was performed with the 
IScript cDNA Synthesis kit (BioRad Laboratories BV, 
Veenendaal, the Netherlands), and primers for HPRT 
(fw: 5′-GACCAGTCAACAGGGGACAT-3′, rv: 
5′-CCTGACCAAGGAAAGCAAAG-3′) were 
obtained from Roche Diagnostics (Almere, the 
Netherlands). RT-qPCR was performed on a BioRad 
CFX96 (CFX Manager software 3.1), using IQ SYBR 
Green Supermix (BioRad). Samples contained 4 ng 
cDNA and were run in duplicates.
Detection of EBV-specific CD8+ T cells
An enzyme-linked immunospot (ELISPOT) assay 
detecting EBV-specific activated CD8+ T cells secret-
ing IFN-γ was used to quantify the EBV-specific 
CD8+ T cell response.27 PBMC were thawed and 
1–2 × 105 cells were incubated in triplicates in the 
presence of pools of CD8+-restricted EBV peptide 
epitopes (1 mg/mL). Peptide-free medium and phyto-
hemagglutinin (PHA; 5 mg/mL) served as negative 
and positive controls, respectively. Responses were 
expressed as the mean number of spot-forming cells 
(SFC) of the three replicates per 106 PBMC. The 
assay was considered experimentally valid if, in the 
presence of the stimulating peptide, SFC was >50/106 
cells and at least threefold higher than in the negative 
control. Background levels were subtracted from the 
data before analysis.
B cell cultures
The purified B cells from HVs were cultured in 
96-well plates at 1 × 106 cells/well in 200 µL culture 
medium (86% RPMI 1640 medium, 10% fetal bovine 
serum (FBS), 2% penicillin–streptomycin, 1% sodium 
pyruvate, 1% non-essential amino acids) alone or sup-
plemented with 0.1 µM CpG oligodeoxynucleotide 
2006 (Invivogen, San Diego, CA, USA) with or 
without 10 nM 1,25(OH)2D3 (Sigma Aldrich, Saint 
Louis, MO, USA). After 7 days, supernatants were 
collected and stored at −20°C until analysis of (anti-
EBNA-1) IgG.
Total IgG and anti-EBNA-1 IgG in culture 
supernatants
Enzyme-linked immunosorbent assays (ELISA) were 
performed to quantify the amount of total and anti-
EBNA-1 IgG in culture supernatants. For the total 
IgG assay,28 human serum with quantified IgG levels 
by nephelometry (Immage 800, Beckman Coulter, 
Mijdrecht, The Netherlands) was used as standard. 
The anti-EBNA-1 IgG ELISA was performed using a 
commercially available kit with recombinant EBNA-1 
precoated plates (88 kDa, sf-9 baculovirus; IBL 
International, Hamburg, Germany). Additionally, a 
qualitative line blot (Euroline EBV profile 2, 
Euroimmun, Luebeck, Germany) was used for the 
detection of antibodies against EBV antigens, includ-
ing EBNA-1 and VCA.
Statistical analyses
Due to non-normal data distribution, median values 
with 25th–75th percentile ranges (Q1–Q3) are pro-
vided for continuous data. Group differences were 
analyzed using the Mann–Whitney U test and within-
group differences between week 0 (T0) and week 48 
(T1) with the Wilcoxon signed-rank test. p-values 
<0.05 were considered statistically significant. 
Statistical analyses were performed using SPSS soft-
ware version 23.0 (IBM Corp., Armonk, NY, USA).
Results
Patient characteristics and vitamin D3 
supplementation effectiveness
In all, 53 RRMS patients completed the SOLARIUM 
study (F/M = 35/18; mean age = 37.5 (±8.2) years; 
median disease duration = 7.3 (4.4–12.0) months; 
mean 25(OH)D = 56.0 (±24.5) nmol/L), of which 30 
were in the vitamin D3 group and 23 in the placebo 
group (Supplementary Table S1). After 48 weeks, an 
increase in serum 25(OH)D-levels was observed in 
the vitamin D3 group (60 (38–85) to 231 (162–250) 
nmol/L; p < 0.001), and not in the placebo group (54 
(43–63) to 60 (36–85) nmol/L; p = 0.380).18
Vitamin D3 supplementation selectively reduces 
anti-EBNA-1 IgG levels
All patients were EBV-seropositive (92% were posi-
tive for EBNA-1, 98% were positive for VCA, and 
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none were negative for both), whereas 38% of the 
patients were CMV-seropositive. No significant dif-
ferences in IgG levels against EBNA-1, VCA, and 
CMV were found between the groups at T0 or T1 (data 
not shown). However, anti-EBNA-1 IgG levels were 
significantly reduced at T1 compared to T0 in the vita-
min D3 group (p < 0.001), but not in the placebo group 
(p = 0.626). No significant change between T1 and T0 
was instead present for anti-EBV VCA and anti-CMV 
IgG levels in either group (Table 1). Moreover, when 
comparing the T1–T0 differences in anti-EBNA-1 IgG 
between the groups, the median difference was signifi-
cantly larger in the vitamin D3 group (−88 (−397 to 
−5) U/mL) than in the placebo group (0 (−66 to +48) U/
mL; p = 0.023; Figure 1). These effects remained 
unchanged when outliers with very high anti-EBNA-1 
IgG levels were removed from the analysis (not 
shown). Within the size limits of the patient cohort, 
further analyses on the patients in the vitamin D3 group 
with the most pronounced decreases of anti-EBNA-1 
IgG did not reveal differences in 25(OH)D levels, 
EBV viral load, or EBV-specific CD8+ T cell response 
(see below).
Vitamin D3 supplementation does not influence 
EBV viral load in PBMC or EBV-specific CD8+ 
T cells
We further explored the potential mechanisms 
underlying the selective reduction of anti-EBNA-1 
IgG upon vitamin D3 supplementation. We hypothe-
sized that vitamin D could reduce antigens available 
to trigger anti-EBNA-1 antibody responses by pro-
moting eradication of EBV-infected cells (as meas-
ured by EBV viral load in PBMCs) via an increase in 
the cytotoxic T cell response against EBV (as meas-
ured by the number of EBV-specific CD8+ T cells). 
However, median EBV DNA copies in PBMC sam-
ples did not significantly change over 48 weeks in 
either of the groups (Table 2). PBMCs from 15 vita-
min D3-supplemented and 15 placebo-administered 
patients were available for detection of activated 
EBV-specific CD8+ T cells secreting IFN-γ. We 
found that 11 vitamin D3 and 9 placebo patients were 
positive responders to the EBV peptide pool. The 
median amount of SFC/106 PBMC was similar for 
both groups at both time points. Also, no significant 
changes were found within groups (Figure 2). 
Table 1. Plasma IgG levels of the patients with RRMS.
Placebo (n = 23) Vitamin D3 (n = 30) p-value*
 T0
M (Q1–Q3)
T1
M (Q1–Q3)
p-value T0
M (Q1–Q3)
T1
M (Q1–Q3)
p-value
Anti-EBNA-1 IgG (U/mL) 432 (351–1280) 429 (297–1290) 0.626 526 (368–1683) 455 (380–1148) <0.001 0.023
Anti-VCA IgG (U/mL) 643 (234–1140) 581 (216–1230) 0.976 374 (180–752) 411 (171–732) 0.311 0.615
Anti-CMV IgG (U/mL) 9 (5–79) 13 (5–79) 0.233 5 (5–73) 5 (5–81) 0.407 0.617
EBNA-1: Epstein–Barr nuclear antigen 1; IgG: immunoglobulin G; VCA: viral capsid antigen; CMV: cytomegalovirus; T0: baseline; T1: week 48;  
Q1–Q3 = 25th–75th percentile.
*Between-group comparisons of the T1–T0 differences.
Table 2. Between and within group comparisons for EBV load.
Placebo (n = 19) Vitamin D3 (n = 24) p-value*
 T0 T1 p-value T0 T1 p-value
EBV copies per 1 × 106 PBMCa 320 (0–662) 203 (0–581) 0.758 75 (0–255) 0 (0–516) 0.170 0.320
EBV copies per 1 × 105 B cellsb 216 (0–716) 149 (0–466) 0.586 57 (0–182) 0 (0–256) 0.795 0.771
Fold change relative to T0 (2−ΔΔCT) 1.31 (0.16–3.17) 1.38 (0.36–3.11) 0.678
EBV: Epstein–Barr virus; PBMC: peripheral blood mononuclear cells; T0: baseline; T1: week 48; HPRT: reference gene; PCR: polymerase chain reaction.
DNA and RNA were extracted from 200 and 800 mL of TRIzol samples containing PBMC, respectively. EBV load was analyzed in extracted DNA, and HPRT 
in synthesized cDNA of extracted RNA using real-time quantitative PCR. Since in a substantial amount of samples (44%), either before or after the intervention, 
EBV could not be amplified, EBV copies of 0 and a CT value of 40 were used for negative samples in order to assess changes in expression over time. Data are 
presented as medians with 25th–75th percentiles.
aEBV copies were calculated for 1 × 106 PBMC based on cell counts prior to storage in TRIzol.
bEBV copies were calculated for 1 × 105 B cells, based on cell counts and B cell proportions determined by flow cytometry. 2−ΔΔCT = normalized EBV load at T1 
relative to T0 for the change in relative expression of EBV to HPRT.
*Between-group comparisons of the T1–T0 differences.
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Therefore, we found no evidence supporting an 
effect of vitamin D supplements on the clearance of 
EBV in the circulation.
Vitamin D reduces total IgG secretion in vitro
Alternatively, antibody secretion of anti-EBNA-1 IgG 
itself may be affected directly by vitamin D. Therefore, 
we performed an in vitro study, aiming to compare 
the anti-EBNA-1 IgG/total IgG indexes. During 
7 days, B cells of EBV-seropositive HVs (n = 12; 
F/M = 9/3; median age = 28.9 (21.5–34.6) years; median 
anti-EBNA-1 IgG index (range) = 8.38 (0.43–9.74)) 
were cultured and stimulated with CpG in the presence 
or absence of 1,25(OH)2D3. Supernatants of conditions 
with 1,25(OH)2D3 showed a significant median reduc-
tion of 48.2% (Q1–Q3 = 43.2%–53.9%; p = 0.002) in 
total IgG levels compared to the ones without 
1,25(OH)2D3. However, in our assays anti-EBNA-1 
IgG levels could not be detected in any of the culture 
supernatants, neither by ELISA nor by line blot (data 
not shown).
Discussion
This study confirmed a selective reduction of anti-
EBNA-1 IgG levels after 48 weeks vitamin D3 sup-
plementation in RRMS patients. Furthermore, we 
explored mechanisms by which vitamin D may affect 
the anti-EBNA-1 antibody response. Results with 
Figure 1. Anti-EBNA-1 IgG levels of patients with RRMS before and after treatment. (a) Within-group comparisons at 
T0 and T1 in the placebo group (n = 23), (b) within-group comparisons at T0 and T1 in the vitamin D3 group (n = 30), and 
(c) between-group comparisons of the anti-EBNA-1 IgG level differences between T1 and T0. Gray lines indicate the 
medians with interquartile ranges.
T0: baseline; T1: week 48.
Figure 2. EBV-specific CD8+ T cells of patients with RRMS before and after treatment. ELISPOT assays were 
performed to detect activated EBV-specific CD8+ T cells secreting interferon-γ. Peripheral blood mononuclear cells 
(PBMC) of the patients with RRMS were thawed and cultured at 1–2 × 105 cells per well in the presence of pools of CD8-
restricted EBV peptides at a concentration of 1 mg/mL. The amount of activated cells is represented by SFC/106 PBMC. 
(a) Within-group comparisons at T0 and T1 in the placebo group (n = 9), (b) within-group comparisons at T0 and T1 in 
the vitamin D3 group (n = 11), and (c) between-group comparisons of the differences in SFC/106 PBMC between T1 and 
T0. Gray lines indicate the medians with interquartile ranges.
EBV: Epstein–Barr virus; T0: baseline; T1: week 48; SFC: spot-forming cells.
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respect to the in vitro effects of vitamin D on antibody 
responses were not conclusive, but we found no ex 
vivo evidence that the number of EBV-specific CD8+ 
cytotoxic T cells and the EBV viral load in PBMC is 
affected by vitamin D3 supplements.
Likewise, Røsjø et al.24 showed that 48 weeks of vita-
min D3 supplementation reduced anti-EBNA-1 anti-
body levels in MS, but not anti-VCA, anti-CMV, or 
anti-Varicella Zoster virus (VZV) antibody levels. 
These and our current results are comparable to those 
of our earlier pilot study.23 In this pilot study, we 
found a decrease of anti-EBNA-1 IgG, but not of total 
IgG levels or any change in B cell differentiation pro-
file in general after 12-week high-dose vitamin D3 
supplements in RRMS.23,29 The consistent findings of 
specific anti-EBNA-1 IgG reductions upon vitamin D 
supplementation in (early) MS may be clinically rel-
evant, especially since several but not all studies 
showed that higher anti-EBNA-1 IgG levels predict a 
higher risk of active MRI-lesions in RRMS.7–10 
Therefore, it is tempting to speculate that the reduc-
tion in anti-EBNA-1 IgG is instrumental for the vita-
min D-associated reduction of active MRI-lesions in 
the SOLAR trial.19 This radiological improvement in 
SOLAR may be the result of optimization of vitamin 
D-related immunological regulatory mechanisms, 
which either affects the anti-EBNA-1 serologic 
response to EBV or in which the immune response to 
EBV serves as a critical effector component. We think 
several mechanisms may explain the reduction in 
anti-EBNA-1 IgG by vitamin D, which may be anti-
gen-specific in essence or not.
First, vitamin D may specifically affect the extent of 
EBNA-1 antigen expression (i.e. the trigger of anti-
EBNA-1 antibody responses) by inducing a better 
elimination of EBV-infected B cells. Indeed, EBV 
viral load correlated positively with anti-EBNA-1 
titers.30 Possibly, vitamin D increases the EBV-
specific CD8+ T cell response against latently infected 
B cells, because vitamin D has been reported to 
increase CD8+ T cell proportions.4 Alternatively, vita-
min D may directly target and impair viral replication 
in EBV-infected cells, which could explain why EBV 
has evolved with a protein (i.e. EBNA-3) that is able 
to block the vitamin D receptor.31 Nonetheless, gen-
eral anti-viral effects of vitamin D have been pro-
posed, probably via induction of peptides disrupting 
viral envelopes (i.e. cathelicidin).32 To explore these 
hypotheses, with the limitation of the available mate-
rial, we quantified the number of EBV-specific CD8+ 
T cells and the EBV viral load in PBMC, but in nei-
ther of them we observed a difference between 
vitamin D-treated and placebo-treated patients. 
However, our sample sizes may have been too small 
to detect effects of vitamin D. Also, effects of vitamin 
D in lymphoid tissue may not be reflected by analysis 
of PBMC.
A second specific mechanism could be a direct effect 
of vitamin D on anti-EBNA-1 IgG secretion, which 
could also reflect an inhibition of plasma cell forma-
tion by vitamin D.16 Therefore, we explored the in 
vitro effect of vitamin D on the anti-EBNA-1 IgG/
total IgG index. In line with the results of Chen 
et al.,16 1,25(OH)2D3 clearly reduced total IgG pro-
duction, but we could not detect any anti-EBNA-1 
IgG with our assays. Sorting and cloning of anti-
EBNA-1-specific B cells, as well as of already dif-
ferentiated antigen-specific plasma cells, may be 
necessary to better study possible effects of vitamin 
D on the differentiation and IgG secretion of anti-
gen-specific cells.
Interestingly, as in vitro but not in vivo total IgG lev-
els are influenced by vitamin D,23,29 there is a differ-
ence in the in vitro and in vivo effects of vitamin D on 
IgG production. As a third scenario, we earlier specu-
lated that the increased anti-EBNA1 IgG levels in MS 
may be the result of the generation of short-lived 
plasma cells in ectopic lymphoid follicles in the 
meninges of MS patients.33,34 The obtained materials 
in SOLARIUM were insufficient to address this 
hypothesis, which would rather require studies in 
complex (animal) models. Additionally, these hypoth-
eses would predict the absence of an anti-EBNA-1 
IgG reduction by vitamin D supplements in EBV-
exposed healthy controls.
Fourth, the reduction of anti-EBNA-1 IgG upon vita-
min D3 supplementation may not be antigen-specific, 
but rather represents a better control of inflammation 
in general. Reduced B cell activation in lymphoid tis-
sue will result in reduced anti-EBNA-1 antibody 
responses, since the EBNA-1 protein is only expressed 
during mitosis (proliferation) of EBV-infected B 
cells.4
In conclusion, our results confirm that high-dose vita-
min D3 supplementation selectively reduces anti-
EBNA-1 IgG levels in RRMS. Reflection of our data 
on several earlier studies on anti-EBNA-1 IgG levels 
and MS MRI outcomes suggests that this may be a 
clinically relevant effect. This observation may either 
support an interaction between vitamin D and EBV in 
MS or reflect a better control of inflammation by vita-
min D in general. Additional studies are necessary to 
further elucidate the underlying mechanism of this 
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effect, which may be multiple and complex. These 
studies should probably use (animal) models enabling 
assessment of local effects within lymphoid tissue 
and the central nervous system (CNS).
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